Matthew W. Johnson

Matthew W. Johnson

Creator
0 followers

Psychopharmacology researcher (JHU); psychedelics and behavior

Executive Order on Psychedelics Discussed in New Podcast
SocialApr 23, 2026

Executive Order on Psychedelics Discussed in New Podcast

Check out the recent podcast with @Ravarora1 about the recent executive order on psychedelics https://t.co/QwoDTN692s

By Matthew W. Johnson
2018 Study Predicts Psilocybin Should Move to Schedule 4
SocialApr 20, 2026

2018 Study Predicts Psilocybin Should Move to Schedule 4

The psychedelic executive order requires government to "initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials ... so that rescheduling ... may proceed as quickly as practicable". My 2018...

By Matthew W. Johnson
FDA Poised to Approve Psychedelics Amid Strong Political Push
SocialApr 18, 2026

FDA Poised to Approve Psychedelics Amid Strong Political Push

It seems clear that the administration is poised to approved psychedelic applications at the FDA. This is strong political momentum & it seems approval is extremely likely so long as phase 3 data resemble phase 2 data. FDA Commissioner Makary: There...

By Matthew W. Johnson
Low Placebo Response Skews Psychedelic Depression Trial Results
SocialMar 31, 2026

Low Placebo Response Skews Psychedelic Depression Trial Results

I was interviewed about a study of GH001, vaporized 5-MeO-DMT, for treatment-resistant depression. I commented that, while promising and encouraging, the thing that popped out to me was the almost complete lack of placebo response in the placebo group. Even...

By Matthew W. Johnson
Head
SocialMar 19, 2026

Head

Enjoyed thinking about the new study by @psybalazs & the critique below by @RCarhartHarris. Clearly Robin's SSRI vs psilocybin is the best & only study to compare head to head & I think psychedelics likely offer improved functioning, limited administration...

By Matthew W. Johnson
Psilocybin Plus Therapy Boosts Quit Rates Sixfold
SocialMar 10, 2026

Psilocybin Plus Therapy Boosts Quit Rates Sixfold

🚨 @NPR spotlights our new JAMA Network Open study: One psilocybin dose + therapy gives 6X better odds of quitting smoking vs. nicotine patch + therapy. Game-changer for tobacco smoking addiction?

By Matthew W. Johnson